The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis
Open Access
- 13 October 2010
- journal article
- research article
- Published by Springer Nature in Molecular Cancer
- Vol. 9 (1) , 271
Abstract
Background: Among the most harmful of all genetic abnormalities that appear in colorectal cancer (CRC) development are mutations of KRAS and its downstream effector BRAF as they result in abnormal extracellular signal-related kinase (ERK) signaling. In a previous report, we had shown that expression of a constitutive active mutant of MEK1 (caMEK) in normal rat intestinal epithelial cells (IECs) induced morphological transformation associated with epithelial to mesenchymal transition, growth in soft agar, invasion and metastases in nude mice. Results from microarrays comparing control to caMEK-expressing IECs identified the gene encoding for serpinE2, a serine protease inhibitor, as a potential target of activated MEK1. Results: 1- RT-PCR and western blot analyses confirmed the strong up-regulation of serpinE2 expression and secretion by IECs expressing oncogenic MEK, Ras or BRAF. 2- Interestingly, serpinE2 mRNA and protein were also markedly enhanced in human CRC cells exhibiting mutation in KRAS and BRAF. 3- RNAi directed against serpinE2 in caMEK-transformed rat IECs or in human CRC cell lines HCT116 and LoVo markedly decreased foci formation, anchorage-independent growth in soft agarose, cell migration and tumor formation in nude mice. 4- Treatment of CRC cell lines with U0126 markedly reduced serpinE2 mRNA levels, indicating that expression of serpinE2 is likely dependent of ERK activity. 5- Finally, Q-PCR analyses demonstrated that mRNA levels of serpinE2 were markedly increased in human adenomas in comparison to healthy adjacent tissues and in colorectal tumors, regardless of tumor stage and grade. Conclusions: Our data indicate that serpinE2 is up-regulated by oncogenic activation of Ras, BRAF and MEK1 and contributes to pro-neoplastic actions of ERK signaling in intestinal epithelial cells. Hence, serpinE2 may be a potential therapeutic target for colorectal cancer treatment.Keywords
This publication has 60 references indexed in Scilit:
- Expression of prostasin and its inhibitors during colorectal cancer carcinogenesisBMC Cancer, 2009
- Plasminogen activator inhibitors regulate cell adhesion through a uPAR‐dependent mechanismJournal of Cellular Physiology, 2009
- Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumorsBMC Cancer, 2008
- Plasminogen Activator Inhibitor-1 Protects Endothelial Cells from FasL-Mediated ApoptosisCancer Cell, 2008
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced CancersJournal of Clinical Oncology, 2008
- Prostasin expression is regulated by airway surface liquid volume and is increased in cystic fibrosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008
- Regulation of Actin Assembly Associated With Protrusion and Adhesion in Cell MigrationPhysiological Reviews, 2008
- Oncogenic BRAF regulates β-Trcp expression and NF-κB activity in human melanoma cellsOncogene, 2006
- Induction of an interferon response by RNAi vectors in mammalian cellsNature Genetics, 2003
- Serine protease inhibitor‐E2 (SERPINE2) is differentially expressed in granulosa cells of dominant follicle in cattleMolecular Reproduction and Development, 2002